Drug Profile


Alternative Names: Eprodisate disodium; Eprodisate sodium; Fibrillex; Kiacta; NC-503

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BELLUS Health
  • Developer Auven Therapeutics; BELLUS Health
  • Class Alkanes; Anti-inflammatories; Small molecules; Sulfonic acids
  • Mechanism of Action Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Amyloid A amyloidosis
  • No development reported Sarcoidosis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for preclinical development in Sarcoidosis in USA (PO)
  • 24 Jun 2018 Biomarkers information updated
  • 21 Dec 2016 Discontinued - Phase-III for Amyloid A amyloidosis in USA, European Union, Russia, Israel, Peru, Mexico, India, Argentina, Turkey, Brazil, Chile, Egypt, Tunisia, Ukraine, Georgia, Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top